The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / After the 2020 Election, What’s in Store for Rheumatology Advocacy?

After the 2020 Election, What’s in Store for Rheumatology Advocacy?

November 22, 2020 • By ACR Advocacy Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Every election is consequential, but the 2020 election turned out to be consequential in ways that were not expected going into Election Day. Turnout eclipsed all-time highs in raw vote totals and may be the highest turnout percentage since the election of 1900. However, the end result of all those ballots largely maintains the status quo for 2021, with the exception of President-Elect Joe Biden. Minimal power shifts—near historic lows across almost every level of government—hold implications for the ACR’s advocacy agenda moving forward.

You Might Also Like
  • What’s in Store for Rheumatology in the 113th Congress?
  • What the Election Means for Rheumatology
  • Advocate for Rheumatology Issues During Election Season

The Congressional Landscape
There will be many new faces in Congress, including at least seven new members of the Senate and close to 60 new members in the House. Educating the freshman crop of legislators about the issues facing rheumatology providers and patients will be extremely important to achieve ACR legislative goals. Additionally, given the Republican gains in the House and the narrow Senate margins (regardless of the election outcomes in Georgia), every vote will be incredibly important to move legislation through either chamber.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Democratic majority in the House narrowed its vote lead, but maintained leadership. This lends itself to smooth reintroduction of many priorities from the 116th Congress to the 117th. Popular legislation, such as prior authorization reform under Medicare and limits to step therapy use, as well as policies supporting growth in the medical workforce, can get a headstart with early reintroduction by sponsors who are continuing to serve in the House.

The Senate is harder to predict due to its tighter margins and possible flip, where we won’t know who the majority leaders will be until January. If Senate Majority Leader Mitch McConnell (R-KY) maintains his position, we can expect he will continue to be incredibly selective about what legislation passed by the House that he allows to be considered in the Senate. The tighter majority margin means any legislation taken up will have to appeal to at least centrist Republicans to have a chance of passing. If Sen. Chuck Schumer (D-N.Y.) becomes majority leader after the Georgia runoffs, we are likely to see a smoother pipeline of legislation from the House to the Senate and a higher likelihood of passage. However, even if both chambers are led by one party, the small margins in the Senate mean that any legislation from the House will have to be further moderated to get through the Senate.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

We expect 2021 and the new Congress and administration to bring a fresh perspective on our current issues. A more comprehensive response to COVID-19 and the pandemic’s medical and financial demands will be top of mind. In this process, we are likely to see renewed discussion of major healthcare overhauls, which would not pass through a McConnell-led Senate and would need to be carefully worded to get through a narrow Schumer-led Senate. It is more likely that popular measures from the 116th Congress, such as utilization management policies and workforce support, will be taken up, while the larger picture continues to be negotiated by elected officials and stakeholders.

Pages: 1 2 3 | Single Page

Filed Under: Legislation & Advocacy Tagged With: election, federal administration, legislation and advocacy, Regulation, state legislation

You Might Also Like:
  • What’s in Store for Rheumatology in the 113th Congress?
  • What the Election Means for Rheumatology
  • Advocate for Rheumatology Issues During Election Season
  • State Legislative Update: Setting the Stage for 2020 & Beyond

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)